MOLECULAR PARTNERS AG -ADR (MOLN) Stock Price & Overview
NASDAQ:MOLN • US60853G1067
The current stock price of MOLN is 4.92 USD. Today MOLN is up by 0.41%. In the past month the price increased by 7.22%. In the past year, price increased by 13.16%.
MOLN Key Statistics
- Market Cap
- 184.004M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.95
- Dividend Yield
- N/A
MOLN Stock Performance
MOLN Stock Chart
MOLN Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to MOLN. When comparing the yearly performance of all stocks, MOLN is one of the better performing stocks in the market, outperforming 73.61% of all stocks.
MOLN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MOLN. MOLN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MOLN Earnings
MOLN Forecast & Estimates
10 analysts have analysed MOLN and the average price target is 12.26 USD. This implies a price increase of 149.09% is expected in the next year compared to the current price of 4.92.
For the next year, analysts expect an EPS growth of 6.91% and a revenue growth -56.25% for MOLN
MOLN Groups
Sector & Classification
MOLN Financial Highlights
Over the last trailing twelve months MOLN reported a non-GAAP Earnings per Share(EPS) of -1.95. The EPS increased by 16.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.19% | ||
| ROE | -56.57% | ||
| Debt/Equity | 0 |
MOLN Ownership
MOLN Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.34 | 402.17B | ||
| AMGN | AMGEN INC | 16.54 | 203.213B | ||
| GILD | GILEAD SCIENCES INC | 16.86 | 182.029B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.15 | 117.075B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.71 | 82.631B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.35 | 42.915B | ||
| INSM | INSMED INC | N/A | 30.852B | ||
| NTRA | NATERA INC | N/A | 29.086B | ||
| BIIB | BIOGEN INC | 11.84 | 27.626B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.26 | 23.193B | ||
| MRNA | MODERNA INC | N/A | 22.014B | ||
| EXAS | EXACT SCIENCES CORP | 341.06 | 19.797B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.775B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MOLN
Company Profile
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 159 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Company Info
IPO: 2014-10-22
MOLECULAR PARTNERS AG -ADR
Wagistrasse 14
Schlieren ZUERICH CH
CEO: Patrick Amstutz
Employees: 159
Phone: 41447557700
MOLECULAR PARTNERS AG -ADR / MOLN FAQ
What does MOLECULAR PARTNERS AG -ADR do?
Molecular Partners AG engages in the provision of development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 159 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
What is the current price of MOLN stock?
The current stock price of MOLN is 4.92 USD. The price increased by 0.41% in the last trading session.
What is the dividend status of MOLECULAR PARTNERS AG -ADR?
MOLN does not pay a dividend.
How is the ChartMill rating for MOLECULAR PARTNERS AG -ADR?
MOLN has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Which stock exchange lists MOLN stock?
MOLN stock is listed on the Nasdaq exchange.
What do analysts say about MOLECULAR PARTNERS AG -ADR (MOLN) stock?
10 analysts have analysed MOLN and the average price target is 12.26 USD. This implies a price increase of 149.09% is expected in the next year compared to the current price of 4.92.